| Literature DB >> 36231912 |
Loris Prosperi1, Giovanni Barassi2, Maurizio Panunzio2, Raffaello Pellegrino3, Celeste Marinucci1, Antonella Di Iulio4, Antonio Colombo2, Marco Licameli2, Antonio Moccia2, Mario Melchionna2.
Abstract
BACKGROUND: The terminology of urinary incontinence (UI) and pelvic floor dysfunctions is complex. It affects quality of life and daily activities in personal, social, and professional fields. Managing UI without pharmacologic therapies is effective with a low risk of adverse effects and a large benefit for increasing continence rates. The aim of this preliminary retrospective observational study is to evaluate the effectiveness of the association between manual therapy and focused mechano-acoustic vibrations in women with nonspecific UI.Entities:
Keywords: focused mechano-acoustic vibration therapy; neuromuscular manual therapy; pelvic floor muscles; urinary incontinence
Mesh:
Year: 2022 PMID: 36231912 PMCID: PMC9564884 DOI: 10.3390/ijerph191912612
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Outcome measures statistical analysis in MyotonPRO parameters.
| Variable * | Count | Mean | SD | ANOVA | |
|---|---|---|---|---|---|
|
| 15 | 1.7 | 0.2 | ||
|
| 15 | 1.6 | 0.2 | ns | ns |
|
| 15 | 1.7 | 0.2 | ||
|
| 15 | 1.7 | 0.06 | ns | ns |
|
| 15 | 11.6 | 1.3 | ||
|
| 15 | 11.2 | 0.8 | ns | ns |
|
| 15 | 11.2 | 1.6 | ||
|
| 15 | 10.6 | 0.2 | ns | ns |
|
| 15 | 206.2 | 27.5 | ||
|
| 15 | 204.4 | 25.7 | ns | ns |
|
| 15 | 204.9 | 37.4 | ||
|
| 15 | 194 | 24.4 | ns | ns |
|
| 15 | 1.8 | 0.4 | ||
|
| 15 | 1.7 | 0.4 | ns | ns |
|
| 15 | 1.7 | 0.3 | ||
|
| 15 | 1.9 | 0.4 | ns | ns |
|
| 15 | 13.8 | 2.2 | ||
|
| 15 | 12 | 2.3 | ns | ns |
|
| 15 | 12.9 | 1.8 | ||
|
| 15 | 12.7 | 1.2 | ns | ns |
|
| 15 | 234.5 | 23.8 | ||
|
| 15 | 238.8 | 29.2 | ns | ns |
|
| 15 | 234.5 | 25.8 | ||
|
| 15 | 241.2 | 32.3 | ns | ns |
|
| 15 | 2 | 0,5 | ||
|
| 15 | 2.15 | 0,09 | ns | ns |
|
| 15 | 2.04 | 0.5 | ||
|
| 15 | 2.12 | 0.4 | ns | ns |
|
| 15 | 11.51 | 0.9 | ||
|
| 15 | 11.07 | 1.1 | ns | ns |
|
| 15 | 11.46 | 1.02 | ||
|
| 15 | 11.63 | 1.4 | ns | ns |
|
| 15 | 231.2 | 29 | ||
|
| 15 | 235.5 | 29.5 | ns | ns |
|
| 15 | 232.1 | 32 | ||
|
| 15 | 230.4 | 34.8 | ns | ns |
|
| 15 | 1.9 | 0.5 | ||
|
| 15 | 1.9 | 0.3 | ns | ns |
|
| 15 | 1.8 | 0.4 | ||
|
| 15 | 2 | 0.4 | ns | ns |
|
| 15 | 12.83 | 1.4 | ||
|
| 15 | 12.93 | 1.6 | ns | ns |
|
| 15 | 11.26 | 0.8 | ||
|
| 15 | 11.16 | 0.8 | ns | ns |
|
| 15 | 231.2 | 29 | ||
|
| 15 | 235.5 | 29.5 | ns | ns |
|
| 15 | 202.2 | 37.3 | ||
|
| 15 | 204.5 | 36.5 | ns | ns |
* p-value refers to the differences between T0 and T2 (Student’s t-test). * p-value refers to the repeated measures ANOVA results. SD: Standard Deviation. MyotonPRO parameters: Adductor muscle D-logarithmic decrement L(left)/R(right); Adductor muscle F-oscillation frequency L(left)/R(right); Adductor muscle S-dynamic stiffness L(left)/R(right); Dorsal muscle D-logarithmic decrement L(left)/R(right); Dorsal muscle F-oscillation frequency L(left)/R(right); Dorsal muscle S-dynamic stiffness L(left)/R(right); Gluteus maximus muscle D-logarithmic decrement L(left)/R(right); Gluteus maximus muscle F-oscillation frequency L(left)/R(right); Gluteus maximus muscle S-dynamic stiffness L(left)/R(right); Rectus abdominis muscle D-logarithmic decrement L(left)/R(right); Rectus abdominis muscle F-oscillation frequency L(left)/R(right); Rectus abdominis muscle S-dynamic stiffness L(left)/R(right).
Outcome measures statistical analysis in PFDI-20 and PFIQ-7 parameters.
| Variable | Count | Mean | S.D | 95% | 95% | ANOVA | |
|---|---|---|---|---|---|---|---|
| 15 | 20.27 | 19.21 | 9.63 | 30.91 | |||
| 15 | 8.05 | 9.24 | 2.93 | 13.17 | 0.00132 | 0.000028 | |
| 15 | 9.79 | 9.43 | 4.56 | 15.01 | |||
| 15 | 3.75 | 7.39 | 0.34 | 7.84 | 0.00499 | 0.000635 | |
| 15 | 27.77 | 18.94 | 17.28 | 38.26 | |||
| 15 | 18.05 | 12.36 | 11.20 | 24.9 | 0.00015 | 0.000000 | |
|
| 15 | 57.84 | 27.45 | 42.64 | 73.05 | ||
|
| 15 | 29.86 | 16.84 | 20.53 | 39.18 | 0.00001 | 0.000000 |
| 15 | 33.65 | 21.33 | 21.83 | 45.46 | |||
| 15 | 13.96 | 12.53 | 7.02 | 20.9 | 0.00030 | 0.000016 | |
| 15 | 11.11 | 16.85 | 1.77 | 20.44 | |||
| 15 | 4.44 | 8.71 | 0.38 | 9.27 | ns | 0.038834 | |
| 15 | 20.95 | 14.92 | 12.68 | 29.21 | |||
| 15 | 8.88 | 11.22 | 2.67 | 15.1 | 0.00183 | 0.000071 | |
|
| 15 | 65.71 | 46.14 | 40.16 | 91.26 | ||
|
| 15 | 27.3 | 28.19 | 11.68 | 42.91 | 0.00072 | 0.000015 |
* p-value refers to the differences between T0 and T2 (Student’s t-test). * p-value refers to the repeated measures ANOVA results.SD: Standard Deviation. Questionnaire parameters: PFDI-20, Pelvic Floor Disability Index; UDI-6, Urinary Distress Inventory; CRADI-8, Colorectal-Anal Distress Inventory;POPDI-6, Pelvic Organ Prolapse Distress Inventory; PFIQ-7, Pelvic Floor Impact Questionnaire.